Published on 27 Feb 2024 on Zacks via Yahoo Finance
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
Theravance Biopharma, Inc. TBPH reported fourth-quarter 2023 adjusted net income of 3 cents per share against the Zacks Consensus Estimate of a loss of 4 cents per share.
The reported income excludes share-based compensation expense and non-cash interest expense and income tax expenses. In the year-ago quarter, the company had reported a loss of 10 cents per share.
The bottom line improved owing to higher collaboration revenues from partner Viatris VTRS.